The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.
Mark T. Fleming
No relevant relationships to disclose
Dana E. Rathkopf
No relevant relationships to disclose
Jackie Gibbons
Employment or Leadership Position - Medivation; Medivation
Stock Ownership - Medivation; Medivation
Amy C. Peterson
Employment or Leadership Position - Medivation; Medivation
Stock Ownership - Medivation; Medivation
Alison Hannah
Consultant or Advisory Role - Medivation; Medivation
David Forer
Employment or Leadership Position - Medivation; Medivation
Stock Ownership - Medivation; Medivation
Howard I. Scher
Research Funding - Medivation; Medivation
Michael J. Morris
No relevant relationships to disclose